Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:396-399
Published online before print July 11, 2005, doi: 10.1161/CIRCULATIONAHA.104.529941
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
112/3/396    most recent
CIRCULATIONAHA.104.529941v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spuentrup, E.
Right arrow Articles by Buecker, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spuentrup, E.
Right arrow Articles by Buecker, A.
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Imaging
Right arrow Arterial thrombosis
Right arrow CT and MRI
Right arrow Embolic stroke

(Circulation. 2005;112:396-399.)
© 2005 American Heart Association, Inc.


Imaging

Molecular Magnetic Resonance Imaging of Atrial Clots in a Swine Model

Elmar Spuentrup, MD; Bernd Fausten, MD; Sylvia Kinzel, VD; Andrea J. Wiethoff, PhD; Rene M. Botnar, PhD; Philip B. Graham, PhD; Stephan Haller, MD; Marcus Katoh, MD; Edward C. Parsons, Jr, PhD; Warren J. Manning, MD; Thomas Busch, MD; Rolf W. Günther, MD; Arno Buecker, MD

From the Departments of Diagnostic Radiology (E.S., S.H., M.K., R.W.G., A.B.), Thoracic and Cardiovascular Surgery (B.F., T.B.), and Laboratory Animal Science (S.K.), Aachen Technical University, Aachen, Germany; EPIX Pharmaceuticals (A.J.W., P.B.G., E.C.P.), Cambridge, Mass; and the Departments of Medicine, Cardiovascular Division (R.M.B., W.J.M.), and Radiology (W.J.M.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.

Reprint requests to Elmar Spuentrup, MD, Department of Diagnostic Radiology, University Hospital, Aachen Technical University, Pauwelsstrasse 30, 52057 Aachen, Germany. E-mail spuenti{at}rad.rwth-aachen.de

Received December 17, 2004; revision received March 2, 2005; accepted March 8, 2005.

Background— The detection and differentiation of intracardiac masses is still challenging and may include neoplasms and thrombi. The aim of this study was the investigation of a targeted, fibrin-specific contrast agent (EP-2104R) for molecular targeted magnetic resonance imaging (MRI) of left atrial clots.

Methods and Results— Chronic human thrombi were surgically implanted in the left atrial appendage of 5 swine. Molecular MRI was performed with a navigator-gated, free-breathing, cardiac-triggered 3D inversion-recovery, black-blood, gradient-echo sequence before and after systemic administration of 4 µmol/kg EP-2104R. MR images were analyzed by 2 investigators, and the contrast-to-noise ratio was calculated. Location of clots was confirmed by autopsy, and the gadolinium concentration in the clots was assessed. Before contrast agent administration, thrombi were not visible on black-blood MR images. After contrast administration, all atrial clots (n=5) were selectively visualized as white spots with a high contrast-to-noise ratio (clot/blood, 29.7±8.0). The gadolinium concentration in the clots averaged 74±45 µmol/L.

Conclusions— The fibrin-specific MR contrast agent EP-2104R allows for selective and high-contrast visualization of left atrial clots by means of molecular targeted MRI.


Key Words: arrhythmia • atrium • imaging • fibrin • thrombus




This article has been cited by other articles:


Home page
J Am Coll Cardiol ImgHome page
R.-J. J.H.M. Miserus, M. V. Herias, L. Prinzen, M. B.I. Lobbes, R.-J. Van Suylen, A. Dirksen, T. M. Hackeng, J. W.M. Heemskerk, J. M.A. van Engelshoven, M. J.A.P. Daemen, et al.
Molecular MRI of Early Thrombus Formation Using a Bimodal {alpha}2-Antiplasmin-Based Contrast Agent
J. Am. Coll. Cardiol. Img., August 1, 2009; 2(8): 987 - 996.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. A. Jaffer, P. Libby, and R. Weissleder
Molecular Imaging of Cardiovascular Disease
Circulation, August 28, 2007; 116(9): 1052 - 1061.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. A. Borger, P. M. Murphy, A. Alam, S. Fazel, M. Maganti, S. Armstrong, V. Rao, and T. E. David
Initial results of the chordal-cutting operation for ischemic mitral regurgitation
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1483 - 1492.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. P. Stracke, M. Katoh, A. J. Wiethoff, E. C. Parsons, P. Spangenberg, and E. Spuntrup
Molecular MRI of Cerebral Venous Sinus Thrombosis Using a New Fibrin-Specific MR Contrast Agent
Stroke, May 1, 2007; 38(5): 1476 - 1481.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza
Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 435 - 441.
[Abstract] [Full Text] [PDF]